Autoantibody Signatures Combined with Epstein–Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma

Peng, Yu‐Hui; Xu, Yi‐Wei; Huang, Linting; Zhai, Tian‐Tian; Dai, Li-Yang; Qiu, Siqi; Yang, Yiling; Chen, Weizheng; Zhang, Liqun; Li, En‐Min; Xu, Li‐Yan

doi:10.1158/1940-6207.capr-14-0397

Cited by 19 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Anti-EBV EUROLINE panel displayed a sensitivity of 77.9% for earlystage nasopharyngeal carcinoma (stages 1 and II) samples in the present study which is higher than values published for EBV DNA test and four-gene methylation panel (sensitivity 51.2% and 64.6%) as reported in the literature by Yang and colleagues (35). Peng and colleagues used an autoantibody panel for screening early nasopharyngeal carcinoma with a sensitivity ranging from 61.1% to 70% (30). Thus, the Anti-EBV EUROLINE panel complements the detection of early nasopharyngeal carcinoma.…”

Section: Discussioncontrasting

confidence: 75%

Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China

Chen

Lu³

et al. 2017

Cancer Prevention Research

Self Cite

View full text Add to dashboard Cite

In this study, we aimed to use the combined detection of multiple antibodies against Epstein-Barr virus (EBV) antigens to develop a model for screening and diagnosis of nasopharyngeal carcinoma (NPC). Samples of 300 nasopharyngeal carcinoma patients and 494 controls, including 294 healthy subjects (HC), 99 non-nasopharyngeal carcinoma cancer patients (NNPC), and 101 patients with benign nasopharyngeal lesions (BNL), were incubated with the EUROLINE Anti-EBV Profile 2, and band intensities were used to establish a risk prediction model. The nasopharyngeal carcinoma risk probability analysis based on the panel of VCAgp125 IgA, EBNA-1 IgA, EA-D IgA, EBNA-1 IgG, EAD IgG, and VCAp19 IgG displayed the best performance. When using 26.1% as the cutoff point in ROC analysis, the AUC value and sensitivity/specificity were 0.951 and 90.7%/86.2%, respectively, in nasopharyngeal carcinoma and all controls. In nasopharyngeal carcinoma and controls without the non-nasopharyngeal carcinoma and BNL groups, the AUC value and sensitivity/specificity were 0.957 and 90.7%/88.1%, respectively. The diagnostic specificity and sensitivity of the EUROLINE Anti-EBV Profile 2 assay for both nasopharyngeal carcinoma and early-stage nasopharyngeal carcinoma were higher than that of mono-antibody detection by immune-enzymatic assay and real-time PCR (EBV DNA). In the VCA-IgA-negative group, 82.6% of nasopharyngeal carcinoma patients showed high probability for nasopharyngeal carcinoma, and the negative predictive value was 97.1%. In the VCA-IgA-positive group, 73.3% of healthy subjects showed low probability. The positive predictive value reached 98.2% in this group. The nasopharyngeal carcinoma risk probability value determined by the EUROLINE Anti-EBV Profile 2 might be a suitable tool for nasopharyngeal carcinoma screening. Cancer Prev Res; 10(9); 542-50. Ó2017 AACR.

show abstract

Section: Discussioncontrasting

confidence: 75%

Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China

Chen

Lu³

et al. 2017

Cancer Prevention Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Such a high false‐negative frequency will prevent the timely diagnosis for some ESCC patients, particularly the symptomless, early‐stage patients. Recent publications have highlighted the importance of combined analysis with multiple serum markers, which were reported to have greater sensitivity and specificity than single‐marker analysis for the detection of various cancers . This study highlights the benefit of the combinational analysis of DKK‐1 and DKK‐1 autoantibody, which had the ability to significantly discriminate ESCC or early ESCC from normal controls, with larger AUC values compared with the markers used alone (Fig.…”

Section: Discussionmentioning

confidence: 59%

Combined detection of serum Dickkopf‐1 and its autoantibodies to diagnose esophageal squamous cell carcinoma

Peng

Guo

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) can be treated effectively if diagnosed at an early stage. We evaluated whether measurement of Dickkopf‐1 (DKK‐1) in combination of DKK‐1 autoantibodies in serum may benefit early diagnosis of ESCC. Serum DKK‐1 and DKK‐1 autoantibodies were measured by enzyme‐linked immunosorbent assay in a training cohort (185 ESCC samples vs. 97 normal controls) and validated in a validation cohort (104 ESCC samples vs. 53 normal controls). Receiver operating characteristic (ROC) was applied to calculate diagnostic accuracy. Testing of DKK‐1 and DKK‐1 autoantibodies together could differentiate ESCC from normal controls (area under the ROC curve [AUC] 0.769, 95% confidence interval (CI), 0.715–0.823, 50.3% sensitivity, and 90.7% specificity in the training cohort; AUC 0.752, 95% CI, 0.675–0.829, 50.0% sensitivity, and 84.9% specificity in the validation cohort). Importantly, the diagnostic performance of the combination of DKK‐1 and DKK‐1 autoantibodies persisted in early ESCC patients (AUC 0.780, 95% CI, 0.699–0.862, 50.0% sensitivity, and 90.7% specificity in the training cohort; AUC 0.745, 95% CI, 0.626–0.865, 53.8% sensitivity, and 84.9% specificity in the validation cohort). Furthermore, the levels of serum DKK‐1 or DKK‐1 autoantibody after surgical resection were lower, respectively, compared with the corresponding preoperative samples (P < 0.05). Our results suggest that measurement of DKK‐1 combined with DKK‐1 autoantibodies is a potentially valuable tool for the early detection of ESCC.

show abstract

“…ELISA was used to detect serum levels of autoantibodies against STIP1 by two investigators (Can-Tong Liu and Xin-Yi Huang) who were blinded to clinical information about ESCC patients and normal controls. ELISA protocol was conducted according to our prior work [ 22 , 25 ]. In brief, recombinant STIP1 protein diluted to a concentration of 0.2 μ g/mL was dispensed in 100 μ L per well volumes into 96-well microtiter plates and incubated overnight at 4°C.…”

Section: Methodsmentioning

confidence: 99%

“…All serum samples were tested in duplicate. Quality control for monitoring of intra-assay deviation or interassay deviation of the ELISA assay was conducted as described in our previous studies [ 22 , 25 ]. Briefly, the intra-assay and interassay coefficient of variations (CVs) for the ELISA method of the detection of autoantibodies against STIP1 were 7.9% and 9.4%, respectively.…”

Section: Methodsmentioning

confidence: 99%

Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Liu

Huang

et al. 2017

Disease Markers

Self Cite

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) remains one of the leading causes of cancer-related mortality around the world. The identification of novel serum biomarkers is required for early detection of ESCC. This study was designed to elucidate whether autoantibodies against STIP1 could be a diagnostic biomarker in ESCC. An enzyme-linked immunosorbent assay was performed to detect serum levels of STIP1 autoantibodies in a training cohort (148 ESCC patients and 111 controls) and a validation cohort (60 ESCC patients and 40 controls). Mann–Whitney's U test showed that ESCC patients in two cohorts have higher levels of autoantibodies against STIP1 when compared to controls (P < 0.001). According to receiver operating characteristic analysis, the sensitivity, specificity, and area under the curve (AUC) of autoantibodies against STIP1 in ESCC were 41.9%, 90.1%, and 0.682 in the training cohort and 40.0%, 92.5%, and 0.710 in the validation cohort, respectively. Moreover, detection of autoantibodies against STIP1 could discriminate early-stage ESCC patients from controls, with sensitivity, specificity, and AUC of 35.7%, 90.1%, and 0.684 in the training cohort and 38.5%, 92.5%, and 0.756 in the validation cohort, respectively. Our findings indicated that autoantibodies against STIP1 might be a useful biomarker for early-stage ESCC detection.

show abstract

Autoantibody Signatures Combined with Epstein–Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma

Cited by 19 publications

References 29 publications

Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China

Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China

Combined detection of serum Dickkopf‐1 and its autoantibodies to diagnose esophageal squamous cell carcinoma

Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About